| Literature DB >> 26520065 |
Xiaochun Peng1, Xianlong Zhang2, Tao Cheng3, Mengqi Cheng4, Jiaxing Wang5.
Abstract
BACKGROUND: The quadriceps-sparing and subvastus approaches are two of the most commonly used minimally-invasive approaches in total knee arthroplasty (TKA). However, the conclusion among studies still remains controversial. The purpose of this meta-analysis was to compare the clinical efficacy of the subvastus and quadriceps-sparing approaches with the standard parapatellar approach in TKA.Entities:
Mesh:
Year: 2015 PMID: 26520065 PMCID: PMC4628282 DOI: 10.1186/s12891-015-0783-z
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Flow chart of literature screening
Characteristics of included studies
| Study-year | Country | Group | Patients (male/female) | Total TKA | Age | BMI | Follow-up | Results favoring |
|---|---|---|---|---|---|---|---|---|
| Chiang 2012 | China | QS | 30 (3/27) | 38 | 69.7 ± 5.3 | 28.6 ± 3.8 | 2 years | MP |
| SP | 30 (3/27) | 37 | 69.8 ± 5.4 | 29.6 ± 3.5 | ||||
| Karpman 2009 | America | QS | 20 (8/12) | 20 | 73 ± 7.4 | 28 ± 4.4 | 6 months | QS |
| SP | 19 (9/10) | 19 | 73 ± 5.1 | 29 ± 4.6 | ||||
| Kim 2007 | Korea | QS | 120 (27/93) | 120 | 65.4 (43–88) | 28.1 (19–36) | 2 years | MP |
| SP | 120 (27/93) | 120 | ||||||
| Lin 2009 | China | QS | 30 (3/27) | 40 | 69.6 (57–78) | 28.1 (20.1–36.9) | 2 month | N.S |
| SP | 30 (3/27) | 40 | 70.2 (56–82) | 29.0 (20.1–36.9) | ||||
| Lin 2013 | China | QS | 35 (5/30) | 35 | 67.7 ± 5 | 26.3 ± 2.5 | 2 years | QS |
| SP | 35 (5/30) | 35 | 68.5 ± 5.5 | 25.9 ± 2.6 | ||||
| Matsumoto 2011 | Japan | QS | 25 (0/25) | 25 | 73.8 ± 1.7 | Not reported | 1 week | QS |
| SP | 25 (0/25) | 25 | 73.7 ± 1.4 | Not reported | ||||
| Shen 2007 | China | QS | 26 (−/−) | 26 | Not reported | Not reported | 12 years | QS |
| SP | 33 (−/−) | 33 | Not reported | Not reported | ||||
| Tasker 2013 | United Kingdom | QS | 46 (17/29) | 46 | 67.3 ± 8.4 | Not reported | 2 years | QS |
| SP | 46 (17/29) | 46 | 68.2 ± 7.5 | Not reported | ||||
| Xu 2013 | China | QS | 26 (7/19) | 35 | 63.5 ± 8.7 | 25.2 ± 3.4 | 3 months | QS |
| SP | 29 (11/18) | 35 | 64.2 ± 9.3 | 25.2 ± 2.3 | ||||
| Roysam 2001 | United Kingdom | SV | 46 (25/21) | 46 | 70.2 | Not reported | 3 months | SV |
| SP | 43 (22/21) | 43 | 69.8 | Not reported | ||||
| Weinhardt 2004 | German | SV | 26 (19/7) | 26 | 69.7 ± 9.1 | Not reported | 13 days | N.S |
| SP | 26 (14/12) | 26 | 73.7 ± 6.8 | Not reported | ||||
| Bridgman 2009 | United Kingdom | SV | 116 (60/56) | 116 | 70.1 ± 8.0 | Not reported | 1 year | SV |
| SP | 115 (59/56) | 115 | 70.9 ± 8.1 | Not reported | ||||
| Sastre 2009 | Spain | SV | 56 (not reported) | 56 | NR | Not reported | 1 year | SV |
| SP | 48 (not reported) | 48 | Not reported | Not reported | ||||
| Pan 2010 | China | SV | 35 (11/24) | 35 | 62.5 (54–70) | 24.8 (19.5–28.6) | 18 months | N.S |
| SP | 33 (9/24) | 33 | 63.2 (50–75) | 24.6 (19.4–28.2) | ||||
| Varela-Egocheaga | Spain | SV | 50 (14/36) | 50 | 68.02 ± 8.14 | 30.97 ± 5.25 | 3 years | SV |
| SP | 50 (13/37) | 50 | 70.64 ± 7.88 | 30.62 ± 3.42 | ||||
| Van Hemert 2010 | Netherlands | SV | 20 (6/14) | 20 | 70.3 ± 11.8 | 29.2 ± 5.5 | 3 months | N.S |
| SP | 20 (7/13) | 20 | 70.9 ± 7.1 | 30.3 ± 5.9 | ||||
| Varnell 2011 | Italy | SV | 18 (11/7) | 20 | 71 ± 6 | 30.96 ± 6.16 | 6 months | MP |
| SP | 15 (5/10) | 18 | 70 ± 7 | 28.15 ± 4.2 | ||||
| Wegrzyn 2013 | USA | SV | 18 (4/14) | 18 | 71 ± 6 | 30.96 ± 6.16 | 2 months | N.S |
| SP | 18 (4/14) | 18 | 70 ± 7 | 28.15 ± 4.2 | ||||
| Jain 2013 | India | SV | 50 (12/38) | 50 | 67 ± 8 | 30 ± 6 | 2 weeks | SV |
| SP | 50 (12/38) | 50 | 64 ± 7 | 31 ± 4 |
BMI body mass index, SV subvastus, SP standard parapatellar, QS quadriceps-sparing, N.S not significant
Risk of bias in included studies
| Study | Random Sequence Generation | Allocation concealment | Blinding of participants | Blinding of outcome assessment | Incomplete Outcome data | Selective reporting | Other bias |
|---|---|---|---|---|---|---|---|
| Kim 2007 | Yes (Randomization table) | Unclear | Unclear | Yes | Yes | Unclear | Unclear |
| Shen 2007 | Yes (Not reported) | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Karpman 2009 | Yes (Computer) | Unclear | Yes | Yes | Yes | Unclear | Unclear |
| Lin 2009 | Yes (Computer) | Yes (Sealed envelope) | Yes | Yes | Yes | Unclear | Unclear |
| Matsumoto 2011 | Yes (Not reported) | Unclear | Yes | Unclear | Yes | Unclear | Unclear |
| Chiang 2012 | Yes (computer) | Unclear | Yes | Yes | Yes | Yes | Unclear |
| Lin 2013 | Yes (Randomization table) | Yes (Sealed envelope) | Unclear | Yes | Yes | Unclear | Unclear |
| Tasker 2013 | Yes (Randomization table) | Yes (Sealed envelope) | Yes | Yes | Yes | Unclear | Unclear |
| Xu 2013 | Yes (Randomization table) | Yes (Sealed envelope) | Unclear | Unclear | Yes | Unclear | Unclear |
| Roysam 2001 | Yes (Random number table) | Yes (Sealed envelope) | Yes | Yes | Yes | Unclear | Unclear |
| Weinhardt 2004 | Yes (Not reported) | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Bridgman 2009 | Yes (Computer) | Yes (Telephone) | Yes | Yes | Yes | YES | Unclear |
| Sastre 2009 | Yes (Random number table) | Yes (Sealed envelope) | Yes | Yes | No | Unclear | Unclear |
| Pan 2010 | Yes (Computer) | Yes (Sealed envelope) | Yes | No | Yes | Unclear | Unclear |
| Varela-Egocheaga 2010 | Yes (Random number table) | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Van Hemert 2010 | Yes (Not reported) | Unclear | Yes | Yes | Yes | Unclear | Unclear |
| Bourke 2012 | Yes (Computer) | Yes (Sealed envelope) | Yes | Yes | No | Unclear | Unclear |
| Wegrzyn 2013 | Yes (Computer) | Unclear | Yes | Yes | Yes | Unclear | Unclear |
| Jain 2013 | Yes (Computer) | Yes (Block schedule) | Yes | Unclear | Yes | Unclear | Unclear |
Meta-analysis of quadriceps-sparing (QS) versus standard parapatellar (SP) approach
| Outcomes | Studies | No. of TKAs (QS/SP) | MD or OR (95 % CI); | Heterogeneity | |
|---|---|---|---|---|---|
| KSS 4–6 weeks | 3 | 101 | 108 | −0.91 [−3.08, 1.25]; |
|
| KSS 3 months | 2 | 138 | 138 | 2.88 [1.17, 4.60]; |
|
| KSS 2 year | 2 | 155 | 155 | 1.75 [0.45, 3.06]; |
|
| VAS 1 weeks | 4 | 124 | 129 | −0.69 [−1.10, −0.29]; |
|
| VAS 4–6 weeks | 3 | 104 | 110 | 0.14 [−0.29, 0.58]; |
|
| Total Complication | 6 | 279 | 287 | 1.00 [0.21, 4.72]; |
|
| Wound infection | 6 | 279 | 287 | 1.05 [0.39, 2.85]; |
|
| Deep vein thrombosis | 6 | 279 | 287 | 0.67 [0.16, 2.92]; |
|
| ROM 1 week | 2 | 64 | 70 | 5.79 [−6.26, 17.85]; |
|
| ROM 4–6 weeks | 3 | 99 | 105 | 3.83 [−2.81, 10.46]; |
|
| ROM 3 months | 2 | 146 | 153 | 4.37 [−6.41, 15.14]; |
|
| ROM 12 months | 2 | 66 | 76 | 10.08 [−7.56, 27.72]; |
|
| ROM 24 months | 4 | 233 | 235 | −0.18 [−1.91, 1.56]; |
|
| Operative time | 7 | 319 | 327 | 18.22 [9.92, 26.51]; |
|
| Blood loss | 4 | 220 | 222 | 0.80 [−39.34, 40.93]; |
|
| Hospital stay | 4 | 215 | 217 | −0.68 [−1.48, 0.12]; |
|
Meta-analysis of subvastus (SV) versus standard parapatellar (SP) approach
| Outcomes | Studies | TKAs (SV/SP) | MD or OR [95 % CI]; | Heterogeneity | |
|---|---|---|---|---|---|
| KSS 4–6 weeks | 2 | 128 | 127 | −1.86 [−8.59, 4.88]; |
|
| KSS 3 months | 4 | 196 | 195 | 1.03 [−10.28, 12.35]; |
|
| KSS 12 months | 2 | 161 | 157 | 3.25 [−0.60, 7.10]; |
|
| VAS 1 weeks | 2 | 132 | 133 | −0.56 [−1.42, 0.29]; |
|
| VAS 4–6 weeks | 3 | 182 | 175 | −0.13 [−0.44, 0.19]; |
|
| VAS 3 months | 3 | 182 | 177 | −0.03 [−0.32, 0.27]; |
|
| VAS 6 months | 2 | 165 | 159 | −0.14 [−0.28, −0.01]; |
|
| Total Complication | 6 | 329 | 315 | 0.81 [0.44, 1.49]; |
|
| Wound infection | 6 | 242 | 233 | 1.11 [0.40, 3.08]; |
|
| Deep vein thrombosis | 5 | 288 | 276 | 5.04 [0.24, 106.22]; |
|
| ROM 1 week | 3 | 163 | 166 | 3.96 [3.20, 4.72]; |
|
| ROM 4–6 weeks | 4 | 230 | 225 | 3.79 [−0.44, 8.03]; |
|
| ROM 3 months | 4 | 230 | 225 | 3.24 [−0.90, 7.38]; |
|
| ROM 12 months | 3 | 214 | 206 | 6.80 [0.94, 12.66]; |
|
| Straight leg raise | 2 | 59 | 61 | −2.77 [−4.07, −1.47]; |
|
| Operative time | 2 | 46 | 46 | 0.11 [−10.37, 10.58]; |
|
| Lateral retinacular release | 4 | 217 | 211 | 0.34 [0.14, 0.79]; |
|
| Blood loss | 3 | 81 | 81 | −100.76 [−223.42, 21.89]; |
|